EP300作为癌症潜在治疗靶标的研究进展
Research Progress of EP300 as a Potential Therapeutic Target for Cancer
DOI: 10.12677/ACM.2022.12101355, PDF,    科研立项经费支持
作者: 罗玉春, 唐婉容*：川北医学院附属医院口腔科，四川 南充
关键词: 癌症；表观遗传；组蛋白乙酰转移酶；EP300；抑制剂；Cancer； Epigenetic Inheritance； Histone Acetyltransferase； EP300； Inhibitors
摘要: 癌症的发生发展是一个长期的、多种因素参与的过程。EP300是组蛋白乙酰转移酶，越来越多的研究表明，EP300的表达和突变与癌症的发生发展密切相关，它能通过乙酰化组蛋白、非组蛋白，或者作为转录辅助因子，将转录因子募集到目标基因的启动子区域促基因转录，来发挥其对癌症的双重作用。本文就EP300对癌症发生发展影响机制的研究进展进行综述。
Abstract: The occurrence and development of cancer is a long-term process involving many factors. EP300 is a histone acetyltransferase. More and more studies have shown that the expression and mutation of EP300 are closely related to the occurrence and development of tumors. It can play its dual role in tumor by acetylation of histones, non-histones, or as a transcription co-factor, recruiting transcrip-tion factors to the promoter region of the target gene to promote gene transcription. The develop-ment of EP300 highly selective small molecule inhibitors is also a hot spot in drug research and de-velopment. In this paper, the mechanism of EP300 on tumor development and its inhibitors were reviewed.
文章引用：罗玉春, 唐婉容. EP300作为癌症潜在治疗靶标的研究进展[J]. 临床医学进展, 2022, 12(10): 9369-9376. https://doi.org/10.12677/ACM.2022.12101355

参考文献

[1] Banaudha, K., Kumar, V. and Verma, M. (2018) Challenges and Opportunities in Social Epigenomics and Cancer. Methods in Molecular Biology, 1856, 233-243. [Google Scholar] [CrossRef] [PubMed]
[2] Holstein, E., Dittmann, A., Kääriäinen, A., et al. (2021) The Burden of Post-Translational Modification (PTM)-Disrupting Mutations in the Tumor Matrisome. Cancers (Basel), 13, Article No. 1081. [Google Scholar] [CrossRef] [PubMed]
[3] Guo, P., Chen, W., Li, H., et al. (2018) The Histone Acetylation Modifications of Breast Cancer and Their Therapeutic Implications. Pathology and Oncology Research, 24, 807-813. [Google Scholar] [CrossRef] [PubMed]
[4] Attar, N. and Kurdistani, S.K. (2017) Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. Cold Spring Harbor Perspectives in Medicine, 7, a026534. [Google Scholar] [CrossRef] [PubMed]
[5] Kraus, W.L., Manning, E.T. and Kadonaga, J.T. (2000) Bio-chemical Analysis of Distinct Activation Functions in p300 That Enhance Transcription Initiation with Chromatin Tem-plates. Molecular and Cellular Biology, 19, 8123-8135. [Google Scholar] [CrossRef] 
[6] Wang, F., Marshall, C.B. and Ikura, M. (2013) Transcription-al/Epigenetic Regulator CBP/p300 in Tumorigenesis: Structural and Functional Versatility in Target Recognition. Cellular and Molecular Life Sciences, 70, 3989-4008. [Google Scholar] [CrossRef] [PubMed]
[7] Delvecchio, M., Gaucher, J., Aguilar-Gurrieri, C., et al. (2013) Structure of the p300 Catalytic Core and Implications for Chromatin Targeting and HAT Regulation. Nature Structural & Molecular Biology, 20, 1040-1046. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, Y., Xue, Y., Shi, J., et al. (2018) The ZZ Domain of p300 Mediates Specificity of the Adjacent HAT Domain for Histone H3. Nature Structural & Molecular Biology, 25, 841-849. [Google Scholar] [CrossRef] [PubMed]
[9] Bhaumik, P., Davis, J., Tropea, J.E., Cherry, S., Johnson, P.F. and Miller, M. (2014) Structural Insights into Interactions of C/EBP Transcriptional Activators with the Taz2 Domain of p300. Acta Crystallographica. Section D, Biological Crystallography, 70, 1914-1921. [Google Scholar] [CrossRef] 
[10] Dancy, B.M. and Cole, P.A. (2015) Protein Lysine Acetylation by p300/CBP. Chemical Reviews, 115, 2419-2452. [Google Scholar] [CrossRef] [PubMed]
[11] Zhu, G., Pei, L., Li, Y. and Gou, X. (2020) EP300 Mutation Is Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Bladder Cancer Patients. Aging (Albany NY), 12, 2132-2141. [Google Scholar] [CrossRef] [PubMed]
[12] Bi, Y., Kong, P., Zhang, L., et al. (2019) EP300 as an Oncogene Cor-relates with Poor Prognosis in Esophageal Squamous Carcinoma. Journal of Cancer, 10, 5413-5426. [Google Scholar] [CrossRef] [PubMed]
[13] Vannam, R., Sayilgan, J., Ojeda, S., et al. (2021) Targeted Degradation of the Enhancer Lysine Acetyltransferases CBP and p300. Cell Chemical Biology, 28, 503-514. [Google Scholar] [CrossRef] [PubMed]
[14] Suganuma, T., Kawabata, M., Ohshima, T., et al. (2002) Growth Suppression of Human Carcinoma Cells by Reintroduction of the p300 Coactivator. Proceedings of the National Academy of Sciences of the United States of America, 99, 13073-13078. [Google Scholar] [CrossRef] [PubMed]
[15] Seo, G.-Y., Park, S.-R. and Kim, P.-H. (2009) Analyses of TGF-beta1-Inducible Ig Germ-Line Gamma2b Promoter Activity: Involvement of Smads and NF-kappaB. European Journal of Immunology, 39, 1157-1166. [Google Scholar] [CrossRef] [PubMed]
[16] Kim, K.B., Kabra, A., Kim, D.W., et al. (2022) KIX Domain Deter-mines a Selective Tumor-Promoting Role for EP300 and Its Vulnerability in Small Cell Lung cancer. Science Advances, 8, eabl4618. [Google Scholar] [CrossRef] [PubMed]
[17] Garcia-Carpizo, V., Ruiz-Llorente, S., Sarmentero, J., et al. (2019) CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines. Molecular Cancer Research, 17, 720-730. [Google Scholar] [CrossRef] 
[18] Bryan, E.J., Jokubaitis, V.J., Chamberlain, N.L., et al. (2002) Mutation Analysis of EP300 in Colon, Breast and Ovarian Carcinomas. International Journal of Cancer, 102, 137-141. [Google Scholar] [CrossRef] [PubMed]
[19] Qian, M., Zhang, H., Kham, S.K., Liu, S., et al. (2017) Whole-Transcriptome Sequencing Identifies a Distinct Subtype of Acute Lymphoblastic Leukemia with Predominant Genomic Abnormalities of EP300 and CREBBP. Genome Research, 27, 185-195. [Google Scholar] [CrossRef] [PubMed]
[20] Henikoff, S. and Shilatifard, A. (2011) Histone Modification: Cause or Cog? Trend in Genetics, 27, 389-396. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, Z., Zang, C., Cui, K., Schones, D.E., et al. (2009) Ge-nome-Wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes. Cell, 138, 1019-1031. [Google Scholar] [CrossRef] [PubMed]
[22] Henry, R.A., Kuo, Y.M. and Andrews, A.J. (2013) Differences in Specificity and Selectivity between CBP and p300 Acetylation of Histone H3 and H3/H4. Biochemistry, 52, 5746-5759. [Google Scholar] [CrossRef] [PubMed]
[23] Das, C., Lucia, M.S., Hansen, K.C., et al. (2009) CBP/p300-Mediated Acetylation of Histone H3 on Lysine 56. Nature, 459, 113-117. [Google Scholar] [CrossRef] [PubMed]
[24] de Almeida Nagata, D.E., Chiang, E.Y., Jhunjhunwala, S., et al. (2019) Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. Cell Reports, 27, 269-281.e4. [Google Scholar] [CrossRef] [PubMed]
[25] Huang, Y.H., Cai, K., Xu, P.P., et al. (2021) CREBBP/EP300 Mutations Promoted Tumor Progression in Diffuse Large B-Cell Lymphoma through Altering Tumor-Associated Mac-rophage Polarization via FBXW7-NOTCH-CCL2/ CSF1 Axis. Signal Transduction and Targeted Therapy, 6, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[26] Liu, Y., Wang, X., Zhu, Y., Cao, Y., et al. (2022) The CTCF/LncRNA-PACERR Complex Recruits E1A Binding Protein p300 to Induce Pro-Tumour Macrophages in Pancre-atic Ductal Adenocarcinoma via Directly Regulating PTGS2 Expression. Clinical and Translational Medicine, 12, e654. [Google Scholar] [CrossRef] [PubMed]
[27] Narita, T., Ito, S., Higashijima, Y., et al. (2021) Enhancers Are Activated by p300/CBP Activity-Dependent PIC Assembly, RNAPII Recruitment, and Pause Release. Molecular Cell, 81, 2166-2182. [Google Scholar] [CrossRef] [PubMed]
[28] Kouzarides, T. (2000) Acetylation: A Regulatory Modification to Rival Phosphorylation? EMBO Journal, 19, 1176- 1179. [Google Scholar] [CrossRef] [PubMed]
[29] Choi, J.-R., et al. (2017) p300-Mediated Acetylation Increased the Protein Stability of HIPK2 and Enhanced Its Tumor Suppressor Function. Scientific Reports, 7, Article No. 16136. [Google Scholar] [CrossRef] [PubMed]
[30] Mahmud, Z., Gomes, A.R., Lee, H.J., et al. (2019) EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity via Modulating FOXO3-Acetylation and Activity in Breast Cancer. Cancers (Basel), 11, Article No. 1067. [Google Scholar] [CrossRef] [PubMed]
[31] Chocarro-Calvo, A., García-Martínez, J.M., Ardila-González, S., et al. (2013) Glucose-Induced Â-Catenin Acetylation Enhances Wnt Signaling in Cancer. Molecular Cell, 49, 474-486. [Google Scholar] [CrossRef] [PubMed]
[32] Feng, L.J., Lin, T.X., Uranishi, H., et al. (2005) Functional Analysis of the Roles of Posttranslational Modifications at the p53 C Terminus in Regulating p53 Stability and Activity. Molecular and Cellular Biology, 25, 5389-5395. [Google Scholar] [CrossRef] 
[33] Pouponnot, C., Jayaraman, L. and Massagué, J. (1998) Physical and Functional Interaction of SMADs and p300/CBP. Biological Chemistry, 273, 22865-22868. [Google Scholar] [CrossRef] [PubMed]
[34] Inoue, Y., Itoh, Y., Abe, K., Okamoto, T., Daitoku, H., Fukamizu, A., Onozaki, K. and Hayashi, H. (2007) Smad3 Is Acetylated by p300/CBP to Regulate Its Transactivation Activity. Oncogene, 26, 500-508. [Google Scholar] [CrossRef] [PubMed]
[35] Yuan, H., Reddy, M.A., Sun, G., et al. (2013) Involvement of p300/CBP and Epigenetic Histone Acetylation in TGF-β1-Mediated Gene Transcription in Mesangial Cells. American Journal of Physiology-Renal Physiology, 304, F601-F613. [Google Scholar] [CrossRef] [PubMed]
[36] Yang, Y., Meng, Q., Wang, C., Li, X., Lu, Y., Xin, X., Zheng, Q. and Lu, D. (2018) MicroRNA 675 Cooperates PKM2 to Aggravate Progression of Human Liver Cancer Stem Cells Induced from Embryonic Stem Cells. Journal of Molecular Medicine (Berlin), 96, 1119-1130. [Google Scholar] [CrossRef] [PubMed]
[37] Merika, M., Williams, A.J., Chen, G., Collins, T. and Thanos, D. (1998) Recruitment of CBP/p300 by the IFN beta Enhanceosome Is Required for Synergistic Activation of Transcription. Molecular Cell, 1, 277-287. [Google Scholar] [CrossRef] 
[38] Ma, C.Q., Huang, S.H., Xu, L., et al. (2020) Transcription Co-Activator P300 Activates Elk1-aPKC-ι Signaling Mediated Epithelial-to-Mesenchymal Transition and Malignancy in Hepatocellular Carcinoma. Oncogenesis, 9, Article No. 32. [Google Scholar] [CrossRef] [PubMed]
[39] Wang, D., Cui, Y., Xu, A., Zhao, L. and Li, P. (2020) MiR-596 Activated by EP300 Controls the Tumorigenesis in Epithelial Ovarian Cancer by Declining BRD4 and KPNA4. Cancer Cell International, 20, Article No. 447. [Google Scholar] [CrossRef] [PubMed]
[40] Bardhan, K., Paschall, A.V., Yang, D., et al. (2015) IFNγ In-duces DNA Methylation-Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer. Cancer Immunology Research, 3, 795-805. [Google Scholar] [CrossRef] 
[41] Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y. and He, B. (2019) Zinc-Dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. Current Topics in Medicinal Chemistry, 19, 223-241. [Google Scholar] [CrossRef] [PubMed]
[42] Coiffier, B., Pro, B., Prince, H.M., Foss, F., et al. (2012) Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma after Prior Systemic Therapy. Journal of Clinical Oncology, 30, 631-636. [Google Scholar] [CrossRef] 

为你推荐